Held by 7 specialist biotech funds
High Convergence**Signal Note: Rock Springs Capital Initiates NGNE Position** Rock Springs' $2.1M entry into Neurogene likely reflects conviction in its lead program GRN-SyN01, an adeno-associated virus (AAV) gene therapy for GM1 gangliosidosis, which targets a rare but well-validated neurodegenerative indication with limited treatment options.
AI analyst context — unlock full analysis
## Signal Note: Baker Bros. Initiates Large Position in Neurogene (NGNE) **Note: The reported position value of ~$20.4B appears to be a data error — NGNE's entire market cap is roughly $1-2B; the ~992K share count at recent prices (~$20-35/share) suggests a position valued in the $20-35M range, consistent with a meaningful but appropriately sized bet.** Baker Bros. building a new position in Neurogene is a high-conviction signal given their concentrated, specialist approach and strong track record in gene therapy plays. NGNE's lead asset is NGN-401, an intrathecally delivered AAV gene therapy for Rett syndrome (MECP2 mutations), with ongoing Phase 1/2 data readouts that have shown early signals of functional improvement in treated patients; additional clinical updates are expected through 2025
+ 5more — see how much conviction went in
See the Full Story